Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 330-335

  Livermore, David M ^a   Mushtaq, Shazad ^a   Warner, Marina ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

AmpC lactamases; Carbapenemases; ESBLs; Extended spectrum lactamases

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFTRIAXONE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; RAZUPENEM; UNCLASSIFIED DRUG;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CITROBACTER; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 67650730262     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp187     Document Type: Article

References (10)

1. Ueda Y, Kanazawa K, Eguchi K et al. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 2005; 49: 4185-96.
2. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
3. Woodford N, Dallow JW, Hill RL et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-9.
4. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9.
5. Karisik E, Ellington MJ, Pike R et al. Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 2006; 58 665-8.
6. Potz NA, Hope R, Warner M et al. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006; 58: 320-6.
7. Doumith M, Ellington M, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
8. Mossakowska D, Ali NA, Dale JW. Oxacillin-hydrolysing β-lactamases. A comparative analysis at nucleotide and amino acid sequence levels. Eur J Biochem 1989; 180: 309-18.
9. Docquier JD, Xerri L. Stability of PTZ 601 (SMP-601) to different clinically-relevant extended-spectrum β-lactamases. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, 2008. Abstract P566. Available at http://www.eccmid.org (12 December 2008, date last accessed).
10. Docquier JD, Xerri L. Interaction of PTZ 601 (SMP-601) and other β-lactams with chromosome-and plasmid-encoded class C β-lactamases. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, 2008. Abstract P565. Available at http://www.eccmid.org (12 December 2008, date last accessed).